Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. - Wikidata - awgldk - TriplyDB

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

http://www.wikidata.org/entity/Q34488796

about

The Philadelphia chromosome in leukemogenesis Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.Childhood acute lymphoblastic leukemia: Integrating genomics into therapy Prognostification of ALL by Cytogenetics Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia.Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04 Favorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study Molecular genetics of B-precursor acute lymphoblastic leukemia Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.Genomic characterization of childhood acute lymphoblastic leukemia.Improving outcomes for high-risk ALL: translating new discoveries into clinical care.Preclinical drug development for childhood cancer.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Predicting relapse risk in childhood acute lymphoblastic leukaemia.Therapeutic approaches to haematological malignancies in adolescents and young adults.Therapies on the horizon for childhood acute lymphoblastic leukemia.Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines.Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.

P2860

Q26745531-000413B2-289C-4E73-937E-1EAA2DE85096 Q27025242-41136C15-7343-4E55-AE68-A6EAC76E9238 Q27851831-5D2D328D-393F-45FD-827A-BF5391296C92 Q28080463-39BA7551-0625-47F1-8A82-713D5C0992CC Q28087446-437DC381-3B33-460D-B91F-94BD9C7256FF Q28087637-4D8B03D5-EC98-4086-AE78-D1BEE1AC2AFC Q33711119-08205439-8AB1-4B54-AEBD-EAA5C7AAD98F Q33762835-5BA8430F-2A03-4C42-A205-5698D84F88F0 Q33998291-F69FBAA1-F277-4D14-88D4-E1F9A21A270D Q34221738-DC8E4DD8-3699-402F-9B97-38A12D585583 Q34371730-4F51DE9E-F95F-4596-918D-D3EB1442A20F Q34598903-7CB804C1-7310-47B2-A094-3AD6C542892F Q34645259-7E680F4F-95D1-42E0-AF37-E59D335E70F7 Q34747454-578B2119-0B9A-470D-B457-1F2969C95872 Q34810036-50495D18-744D-447F-BAA5-D7D080159F8F Q34820210-D185A6E5-9C7D-4910-B739-B9136EF38A0C Q34915917-5726F28C-00BD-4391-B47F-F75FE3E5E237 Q35004970-5B5B5DC1-009D-48CB-9D28-6622F05CDECD Q35112199-7F5DB760-AF90-4D87-803F-5F347B660B6D Q35602127-4542A592-625E-4D14-AFCE-0944F53E560C Q36128159-3A1F5B3E-876F-47A2-959E-1F0D09CB51F7 Q36201257-382E6AC9-0D21-443C-94AC-354587D2BCE8 Q36290242-33A2ACC0-3A7C-47DE-9E90-E9E0E136BD1E Q36752634-2C259077-1318-43C2-B759-AE36C3F63069 Q36811503-118DCAE5-17ED-48D8-ADB4-932592635C3A Q36833021-2420D524-0DB1-4FA3-BB00-DB3F800EEAF7 Q37060668-738E50C9-74A9-433A-90A7-E81A323B1C23 Q37165093-0BBD6614-EBE6-4775-86DB-C3BA37A7CEC7 Q37252283-95A2A8AF-FDB7-4643-BD8E-787B98361AF3 Q37359118-B93C078E-3421-4528-A29A-BA2AE98BB433 Q37849259-17F46E3B-7E1D-491F-A222-2B4231D09DA4 Q38014543-D63A7490-AB63-4233-9ACA-C0C04B9BDC52 Q38079288-BD737A57-D792-4E68-8104-BA2FBFF3F965 Q38117685-06CF57B4-4287-410F-B982-8DBEDB32ECB3 Q38134399-57F559DF-F9C9-4BD0-AEC1-FC946FD88BE9 Q38504437-3051A7F4-E6BA-4C5C-BC56-73FB9C9223D6 Q38616796-D17AE82B-C1F5-442E-B77E-FB470DB0108A Q38698520-23073428-F622-40C9-8E83-2578442F7D6B Q38708757-FE4CA480-A6C0-4EEE-89C1-CEB5141322E4 Q38843371-2F4CD01F-C314-4744-9366-3BFED4315D2E

P2860

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

http://www.wikidata.org/entity/Q34488796

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical outcome of children w ...... treated between 1995 and 2005.

@ast

Clinical outcome of children w ...... treated between 1995 and 2005.

@en

Clinical outcome of children w ...... treated between 1995 and 2005.

@nl

type

label

Clinical outcome of children w ...... treated between 1995 and 2005.

@ast

Clinical outcome of children w ...... treated between 1995 and 2005.

@en

Clinical outcome of children w ...... treated between 1995 and 2005.

@nl

prefLabel

Clinical outcome of children w ...... treated between 1995 and 2005.

@ast

Clinical outcome of children w ...... treated between 1995 and 2005.

@en

Clinical outcome of children w ...... treated between 1995 and 2005.

@nl

P1433

Q34488796-65F0EF84-3BF0-4A37-BAED-637A549BAEA8

P1476

Q34488796-9AB22AE4-FFC2-46E4-9488-035F1A596615

P2093

Q34488796-135B1805-DBB6-49D9-BC48-B320A8D5C3E2

Q34488796-249047FC-198A-449A-A8BA-3EF233E2A9B4

Q34488796-294CCA31-D600-4465-B612-43F069B3A7B7

Q34488796-35371CE3-29FD-46C6-BBA8-9185943AE316

Q34488796-4F7A20E2-7966-4992-886C-06F54A0AB327

Q34488796-61CD13E7-DBE9-4F7E-921C-02598351503F

Q34488796-728759CE-F1A5-4F41-BD88-6E20B5FE58E4

Q34488796-7F0F23D2-C6C8-469A-87CB-B3752AC7802C

Q34488796-82F2730D-1B28-47F1-A9FD-2185A4692590

Q34488796-A5337789-6854-4CDF-8599-51D816420DF2

P2860

Q34488796-04CAAA8B-95E8-4797-A9EA-A2D4F535F6E0

Q34488796-1AA676A0-5327-4B32-BE3E-C7A6D4D717DB

Q34488796-1FBF2054-B07C-4B89-917C-20348AD38DE8

Q34488796-24DAE181-3BE4-467F-BDC5-3CB49D14F2DE

Q34488796-2A1DDE30-2B4E-41F7-B244-36148821C456

Q34488796-323CA72F-7596-4AD6-81FC-479207BA51F5

Q34488796-404EFD8E-F9BE-4B94-9267-13EE77DE6E36

Q34488796-64B3A985-A94C-4643-BAE6-6C7A0CA77A77

Q34488796-7597596D-AFB0-43C7-95F0-2D695A56A739

Q34488796-8335E6AD-6654-4EB9-9E9B-639442195E86

P304

Q34488796-0925AC33-58D3-43B4-84FC-3099BD257EE9

P31

Q34488796-DE138297-953D-4360-B585-CA6F262910E8

P356

Q34488796-95F6E3B3-27B7-484D-A862-136593A6F4B9

P407

Q34488796-1F5021CA-B2F4-4076-ADC8-F5B15BE69603

P433

Q34488796-827CD370-0BEC-470C-AA4C-46C4C5E961D8

P478

Q34488796-9FF2D817-06B9-4893-BC6B-718637C178A2

P50

Q34488796-17B63DD5-FBC1-44FC-8B90-904604E8BF6F

Q34488796-28D6BD7A-A02B-4113-9CC9-C33FA1E54AB7

Q34488796-457C9471-9E84-4AA2-8DA9-77B0A39F4DA8

Q34488796-9E51EDC8-C9AE-4479-A7B7-6D8B955BBA05

Q34488796-B1D7AE20-BF97-4254-969D-9953D12D0658

P577

Q34488796-23001690-55B9-4867-85EA-E7FF1D94C549

P5875

Q34488796-94DC8399-D956-41D3-9E2B-F1CB8FC168EE

P698

Q34488796-83D14D6C-B941-4FE5-843A-FB998479E06F

P921

Q34488796-654252E9-CB46-435F-AAEF-694FC1C11A40

P932

Q34488796-4169F45D-FB1A-4876-B233-529825865DCF

P356

JCO.2010.30.1325

P1433

Journal of Clinical Oncology

P1476

Clinical outcome of children w ...... treated between 1995 and 2005.

@en

P2093

André Baruchel

http://www.w3.org/2001/XMLSchema#string

Atsushi Manabe

http://www.w3.org/2001/XMLSchema#string

Keizo Horibe

http://www.w3.org/2001/XMLSchema#string

Kim Vettenranta

http://www.w3.org/2001/XMLSchema#string

Lewis B Silverman

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Valsecchi

http://www.w3.org/2001/XMLSchema#string

Maurizio Aricò

http://www.w3.org/2001/XMLSchema#string

Stefania Galimberti

http://www.w3.org/2001/XMLSchema#string

Valentino Conter

http://www.w3.org/2001/XMLSchema#string

Vaskar Saha

http://www.w3.org/2001/XMLSchema#string

P2860

Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.

Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review.

P304

4755-4761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.30.1325

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Stephen P Hunger

Martin Schrappe

Gabriele Escherich

P577

2010-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46578611

http://www.w3.org/2001/XMLSchema#string

P698

20876426

http://www.w3.org/2001/XMLSchema#string

P921

P932

3020705

http://www.w3.org/2001/XMLSchema#string